DMPS Challenge Test: Measuring Heavy Metals Correctly
Why a normal blood test can miss a real burden, how the mobilisation test works and what the number on the lab report really tells you.
What this is about, and what it is not
This article goes deeper into exactly one building block of heavy metal diagnostics: the challenge or mobilisation principle using DMPS. It is about the question of what the test measures, how it works and how you can read its result. You will find the big overview of the individual metals in the pillar article on heavy metals, and the comparison of the measurement methods in the article Blood, urine or hair.
When the first number says: everything is fine
Many people with unexplained exhaustion, with brain fog or with diffuse complaints know this moment: at some point you have a heavy metal test done. The result comes back, the value in the blood is unremarkable, and you hear the sentence everything is fine. Yet nothing about how you feel has changed. It is precisely at this point that the question of the challenge test comes up.
The DMPS challenge test, also called the DMPS mobilisation test, is one of the most misunderstood investigations in environmental medicine. One side sells it as a proof machine for a poisoning. The other dismisses it completely, because clean reference values are lacking. Both positions fall short, and in this article I want to calmly explain to you what lies in between.
My position upfront, so you know where the text is heading: the challenge test measures no diagnosis. It measures mobilisability, that is, how much a chelating agent can release from your tissues. That can be useful information when it is read in the context of symptoms, history of sources and course over time. And it can be a dangerous number when someone misuses it in isolation as a verdict.
A normal value measures what is currently floating in the blood. Not what is stored in the tissue. It is precisely this gap that the challenge test tries to close, and it is precisely here that its strength and its limitation lie close together.
Why the normal test can miss a real burden
Many people who come to me already have a blood test or a simple urine test behind them. The finding was unremarkable. And still the feeling remains that something is not right. To resolve this, it is worth looking at what these tests actually measure.
Blood is primarily a transport medium, not a storage organ. It shows what is circulating right now, not what is bound in the tissue. A large part of the relevant heavy metals, however, migrates out of the blood into the tissue, into the kidney, into the bone, into the nervous system. There it sits, in part for years. A baseline urine test can then be unremarkable even though the stores are occupied.
Blood moment versus tissue store, schematically
Bar width stands for the relative residence time in the store, not for absolute values. The core message: the standard test shows above all the short-term transport fraction, not the cumulative tissue burden.
This is where the idea of the challenge test comes in. Instead of only measuring what the body is currently excreting on its own, you give a chelating agent and look at what can additionally be released from the tissue under its influence. You shift the equilibrium briefly, so to speak, and capture what ends up in the urine in the process. I go deeper into the broad method comparison between blood, urine and hair separately in the article Measuring heavy metals: blood, urine or hair.
What DMPS is and why this particular molecule
DMPS stands for 2,3-dimercaptopropane-1-sulfonic acid, known in the pharmacy as Dimaval, internationally also as Unithiol. It is a water-soluble molecule with two free sulphur groups. It is precisely these sulphur groups that are the key, because mercury and some other metals bind to sulphur with high affinity.
To put it visually, DMPS clamps a metal ion firmly with two grippers at the same time and forms a stable complex that the kidney can pass. This complex is excreted via the kidney. That is the whole trick: DMPS binds sulphur-affine metals and makes them water-soluble, so that the body can release them via the urine.
Who: Hurlbut and colleagues gave five healthy volunteers 3 mg per kilogram of DMPS intravenously and tracked the course in blood and urine.
What: DMPS is rapidly converted to disulphides and excreted via the kidney. The half-life of the parent molecule was around 1.8 hours, the oral bioavailability about 39 percent. Mercury excretion closely followed DMPS excretion.
What this means for you: This explains why the urine is collected within a defined time window after the dose. DMPS is only active for a limited window.
Hurlbut KM et al. Pharmacokinetics of DMPS after intravenous administration. J Pharmacol Exp Ther. 1994;268(2):662-668.Important for understanding and for an honest assessment: DMPS is not a selective mercury probe. It also releases other sulphur-affine substances, among them essential trace elements. More on this later, because it is the reason why the test is not a harmless routine check.
How the DMPS mobilisation test works
The procedure follows a simple logic: you measure once before the dose and once afterwards, and the difference shows how much can additionally be mobilised under DMPS. In practice this looks like five steps.
Baseline urine before the dose
First a urine sample is obtained without a chelating agent. It shows the spontaneous excretion, that is, what the body is currently getting rid of on its own. This baseline value is the comparison basis. It also makes sense to leave a time gap from the last larger consumption of fish, because methylmercury from fish can briefly raise the mercury value.
Administration of DMPS
DMPS is given, classically intravenously, in other protocols also orally. The dose is adjusted to body weight and kidney function. The intravenous route takes effect faster and is more predictable, the oral route is lower-threshold but has a lower bioavailability. Which variant makes sense depends on the individual case.
Collected urine within a defined time window
After the dose, the urine is collected over a fixed time window, depending on the protocol over several hours, often in the range of around 4 to 6 hours, in older protocols also over 24 hours. This window results from the pharmacokinetics: DMPS is active only for a limited time and is then excreted.
Relating to creatinine
The metals measured are usually related to creatinine, in order to make different urine dilutions comparable. But it is precisely here that a source of error lies: shortly after a chelating dose, creatinine excretion can fluctuate, which can distort the corrected value. A seemingly high value is therefore not automatically a high value.
Evaluation in a specialised lab
The collected urine is analysed in the lab for mercury and further metals. The result shows how much was mobilised under DMPS. And then the truly important part begins: the interpretation. Because a number alone says nothing as long as you do not place it in the overall context.
Let one common misunderstanding be cleared up right here: the challenge dose is a diagnostic measure, not a treatment cycle. It does excrete metals, but a structured chelation is clearly to be distinguished from it. What such a chelation looks like in concrete terms I describe separately in the article Chelation therapy: procedure, duration and what to expect.
What the test reliably shows: mobilisability
There is a part of the evidence that is genuinely solid. Several independent human studies show that DMPS reliably increases metal excretion in the urine by a multiple. That is well documented, and that is exactly what the test can do.
Who: Torres-Alanis and colleagues gave eleven people concerned about amalgam 3 mg per kilogram of DMPS intravenously and measured ten elements in the urine before and after the dose.
What: Mercury rose by 3- to 107-fold. At the same time, copper, selenium, zinc and magnesium rose markedly, while manganese, chromium, cobalt, aluminium and molybdenum remained unchanged.
What this means for you: DMPS flushes out not only mercury but also important minerals along with it. The test is therefore not a selective probe and not a harmless routine check.
DOI: 10.1081/clt-100102382 Torres-Alanis O et al. J Toxicol Clin Toxicol. 2000;38(7):697-700.Who: Aposhian described and used the standard challenge protocol with 300 mg DMPS and collected urine over 0 to 6 hours in students, dental personnel and arsenic-exposed individuals.
What: In dental personnel, mercury excretion after DMPS rose by 88-, 49- and 35-fold. In students with amalgam, roughly two thirds of the excreted mercury came from the fillings.
What this means for you: The test can show that amalgam can be a real mercury source. But it describes mobilisability, not a diagnosis.
DOI: 10.1289/ehp.98106s41017 Aposhian HV. Environ Health Perspect. 1998;106 Suppl 4:1017-1025.Who: Aposhian and colleagues gave 300 mg DMPS orally to people with and without amalgam and correlated mercury excretion with the amalgam score.
What: In the amalgam group, excretion rose from 0.70 to 17.2 micrograms, without amalgam from 0.27 to 5.1. The correlation with the amalgam score was highly significant.
What this means for you: The test responds measurably to the amalgam source. This supports its usefulness as a measure of exposure, not as proof of disease.
DOI: 10.1096/fasebj.6.7.1563599 Aposhian HV et al. FASEB J. 1992;6(7):2472-2476.With occupational exposure too, the provoked value reflects the exposure. In dental technicians and dentists, the post-DMPS value was a better marker for the kidney burden than the simple baseline value (Gonzalez-Ramirez 1995), and in workers with mercury-containing skin lotion, excretion rose by 38- to 87-fold (Maiorino 1996). An older German-language paper found a 6- to 7-fold increase, with roughly half of the scatter explained by the number of amalgam fillings (Zander 1992).
Mobilisability does not mean total burden
An important caveat: a single dose of DMPS reflects above all the more recent exposure. It barely captures the deep, slow body stores.
In a model experiment in rats, two DMPS doses lowered the mercury content of the kidney by about 30 to 50 percent, with an estimated 17 to 30 percent of the kidney burden mobilised (Nerudova 2000). In other words: even several doses reach only a part of what is stored.
For you this means that a single measurement can give an indication of mobilisability. But it does not mirror your total body burden, and it can neither prove nor rule it out.
%The honest controversy: why medical societies warn
Now comes the part that the test shops like to leave out, and that for me is the most important. As well documented as the mobilisation is, the evidence for the truly decisive question is just as thin and sobering: does a high value prove a poisoning? The honest answer is no.
The central problem: there are no broadly validated reference ranges for urine after a chelating dose. With a normal lab value, you compare against an established normal range. With provoked urine, exactly this comparison value is missing. A high value thus stands, as it were, without a yardstick.
Who: Ruha systematically worked through the problems of challenge tests with DMSA, DMPS and EDTA, including reference ranges and creatinine correction.
What: There is no standardised, validated challenge test and no established reference ranges for provoked urine samples in healthy people. A creatinine correction shortly after the dose can even artificially raise values.
What this means for you: A high post-DMPS value cannot be compared against an established normal value, because this normal value for provoked urine does not exist.
DOI: 10.1007/s13181-013-0350-7 Ruha AM. J Med Toxicol. 2013;9(4):318-325.Who: Weiss and colleagues had 74 patients with a challenge test result from a toxicology registry reassessed by certified toxicologists.
What: Only 3 of 74 cases actually had a heavy metal exposure. The positive predictive value was 4.3 percent. Patients with a challenge test did not have toxicological findings any more frequently than the comparison group.
What this means for you: An abnormal challenge test, on its own, says very little about whether a poisoning really exists.
DOI: 10.1080/15563650.2021.1941626 Weiss ST et al. Clin Toxicol (Phila). 2021;60(2):191-196.Who: Vamnes and colleagues gave DMPS intravenously to four groups: people with alleged amalgam complaints, healthy amalgam carriers, people whose amalgam had been removed and those who never had amalgam.
What: The test could not distinguish patients with complaints from complaint-free amalgam carriers. It only confirmed the generally higher mercury burden in amalgam carriers. A follow-up paper found the same pattern in the blood as well.
What this means for you: The value can say something about your amalgam burden, but nothing about whether your complaints come from the mercury.
DOI: 10.1177/00220345000790031401 Vamnes JS et al. J Dent Res. 2000;79(3):868-874. · Vamnes JS et al. Sci Total Environ. 2003;308:63-71.You can see it: here two things meet that are both true. DMPS mobilises metals, that is documented. And the mobilised value proves no poisoning, that is also documented. The art lies in holding both at the same time, instead of cherry-picking one side.
When the test can be worthwhile, and when not
If the test delivers no diagnosis, then what is it for at all? The answer: it can be a building block when the question fits the method. What matters is the context, not the wish for a single proving number.
Rather worthwhile when
- a plausible source of exposure is in the history, for example years of occupational exposure
- there is a matching symptom burden that other causes do not sufficiently explain
- the question is about mobilisability, not about proof of a poisoning
- it is about a course over time, that is, the comparison over time under the same conditions
- the value is deliberately read as one piece of a mosaic alongside other findings
Rather not worthwhile when
- it is used as a broad screening without any suspicion at all
- a one-off snapshot is meant to be interpreted as a diagnosis
- the number alone is meant to decide on a treatment
- it creates fear instead of giving orientation
- it is about chronic cadmium burden, for which DMPS is not a suitable tool
Viewed through the lenses of functional and PNEI-oriented medicine, the test is never an end in itself. It is a question put to the metabolism: how much can be mobilised under defined conditions, and how does this change when source, mineral status and detoxification capacity change. From the toxicological lens comes the reminder not to confuse this question with the question of a diagnosis. Both lenses together give an honest picture.
I use the challenge test, if at all, as one building block within the clinical overall picture, never as a standalone proof. A single lab value cannot justify a treatment. A person's story can, and the test might be one building block in it. This order matters to me: first the overall picture, then the number, not the other way around.
What the number on the lab report means, and what it does not
When you hold a finding with an elevated post-DMPS value in your hand, the first reaction is often alarm. That is understandable, and in its sharpness it is usually unfounded. Let us place the number in context together.
What an elevated value says
- that under DMPS, metal was mobilisable
- that a source can be plausible, for example amalgam or occupational exposure
- that a starting point for monitoring over time emerges
- that it can make sense to look at the overall picture more closely
What an elevated value does not say
- that a poisoning exists
- that your symptoms definitely come from it
- that a treatment is necessarily required
- how high your total body burden is
The reverse case is important too. A low or borderline value proves neither freedom from complaints nor harmlessness. A single dose of DMPS reaches the deep stores only partly, which is why a moderate value can well be relevant depending on source and mineral status, while a high value in someone with harmless mobilisability may mean little. The number only gains its meaning from the context.
In my practice I see that the greatest uncertainty does not come from high values but from values without context. As soon as a value is placed next to the history of sources, symptoms, mineral status and course over time, it loses its terror and gains in informative value. This is a clinical observation and not a study result, but it matches what the data suggest: the number is a building block, not a verdict.
Safety and the underestimated loss of minerals
A frequent keyword when researching is the side effects of DMPS. The good news first: DMPS is regarded overall as well tolerated. The more important news: tolerated does not mean arbitrarily harmless, and it is precisely here that things become interesting for the metabolism.
Who: Abouyannis and colleagues carried out a dose escalation of oral and intravenous unithiol, that is, DMPS, in 64 healthy adults and recorded adverse events completely.
What: No dose-limiting toxicities and no serious adverse events occurred. The reported events were mild to moderate, and even 1500 mg orally was well tolerated.
What this means for you: DMPS appears to be well tolerated. But this does not mean that the test is sensible for everyone without weighing things up.
DOI: 10.1016/j.ebiom.2025.105600 Abouyannis M et al. EBioMedicine. 2025;113:105600.The real Achilles heel is not a dramatic acute reaction but the loss of minerals. Remember the Torres-Alanis study: DMPS increases not only mercury excretion but also that of copper, zinc, selenium and magnesium, in part likewise by a multiple. Viewed through the PNEI lens, the test thus directly touches the mineral balance.
Why the mineral balance has to be thought of as well
Caution is also warranted with known allergies to DMPS and with impaired kidney function, because the excretion runs via the kidney. I draw the larger arc to risks, loss of minerals and sensible accompaniment separately in the article Chelation therapy: side effects, risks and loss of minerals. DMPS is only one of several chelating agents. How the oral relative DMSA differs from it, for example, you can read in the article DMSA: the oral chelating agent in detail.
The DMPS test compared with other methods
The challenge test is not the only diagnostic tool, and it is also not the best one for every question. It is worth placing it alongside the other methods, without going into them in detail here.
The spontaneous urine and the blood test show the current, circulating fraction and are well suited to mapping an ongoing exposure. The hair mineral analysis roughly mirrors the past few months, but is prone to external contamination and is not suitable as the sole basis for decisions. You can read more on this in the article Hair mineral analysis for heavy metals: possibilities and limits. The DMPS challenge test, in turn, asks about mobilisability from the tissue-blood equilibrium. Which test fits which question I compare systematically in the article Measuring heavy metals: blood, urine or hair.
| Statement | Evidence | Limitation |
|---|---|---|
| DMPS markedly increases metal excretion in the urine | Solid human evidence | small observational and challenge studies, no large RCTs |
| Post-DMPS value correlates with exposure and amalgam score | Several human studies | reflects above all more recent exposure, not the deep stores |
| The test proves a poisoning | Not supported | positive predictive value only 4.3 percent, reference values lacking |
| The test separates symptomatic from complaint-free people | Not supported | controlled studies found no distinction |
| Pharmacokinetics justify the time window of the collection | Pharmacologically documented | single studies, half-life of the parent molecule around 1.8 hours |
| DMPS also excretes essential trace elements | Human study | relevant for loss of minerals, individually variable in extent |
| DMPS is well tolerated | Phase 1 study | caution with allergy and impaired kidney function |
| DMPS is suitable for chronic cadmium burden | Not established | not a suitable tool for cadmium |
“The challenge test measures how much can be released. It does not measure whether you are ill. Keeping these two sentences apart is the whole art.”
Shukri Jarmoukli, ViveCura BerlinAnd now you know why the unremarkable first number need not mean anything yet, and why a high second number is likewise not a verdict yet. Both are fragments of a picture that only becomes readable in context. When the step from diagnostics to chelation follows from this picture, I describe it in the article on chelation therapy.
Frequently asked questions about the DMPS challenge test
How can you test whether you have heavy metals in your body?
There are several routes that answer different questions. Blood shows the fraction currently circulating, spontaneous urine the current excretion, hair roughly the past few months. The DMPS challenge test adds to these by using a chelating agent to release metals from the tissue-blood equilibrium and measuring them in the urine. So it shows mobilisability, not automatically a poisoning.
What does a DMPS test at the doctor cost?
The cost is made up of the medical service, the DMPS preparation and the lab analysis of the collected urine. As an individual health service, the test is usually billed privately. The exact figures depend on the range of metals measured and on the lab, and should be discussed transparently before it is carried out.
Is the DMPS challenge test worthwhile at all?
It can be worthwhile when three things come together: a plausible source of exposure, a matching symptom burden and the question of mobilisability or of change over time. As a pure screening test without suspicion, or as the sole proof of a poisoning, it is not suitable, because validated reference values for provoked urine are lacking.
Does an elevated DMPS value prove a poisoning?
No. An elevated post-DMPS value proves that the body can mobilise metal, not that a poisoning exists. Even people without relevant exposure excrete metals after DMPS. A prospective cohort found a positive predictive value of only 4.3 percent. The value is one building block in context, not a verdict.
Why was my blood test normal even though I have symptoms?
Blood is primarily a transport medium and shows above all the more recent exposure. A large part of the heavy metals is stored in tissue, for example in the kidney, bone or nervous system. An unremarkable blood or spontaneous urine value therefore does not reliably rule out a tissue burden, but conversely also proves no hidden burden.
How exactly does the test work?
First a baseline urine is collected. Then DMPS is given, orally or intravenously. Afterwards the urine is collected over a defined time window, because DMPS is rapidly excreted via the kidney. The metals measured are related to creatinine and evaluated in a specialised lab. The decisive thing afterwards is the interpretation in the overall context.
What side effects does DMPS have?
DMPS is regarded as well tolerated. A phase 1 study in 64 healthy adults found no serious adverse events. What matters are allergic reactions and the fact that DMPS excretes not only heavy metals but also essential trace elements such as copper, zinc, selenium and magnesium. Caution is warranted with impaired kidney function.
Does the test also capture deeply stored heavy metals?
Only partly. A single dose of DMPS reflects above all the more recent exposure and barely reaches the slow, deep body stores. In a rat model, roughly 17 to 30 percent of the kidney burden was mobilised. A single measurement therefore does not mirror the total body burden.
How does the DMPS test differ from a normal urine test?
The normal urine test measures what the body is currently excreting on its own. The DMPS test measures what can additionally be released from the tissue under the influence of a chelating agent. The first shows the current excretion, the second the mobilisability. These are two different questions.
Why do medical societies criticise the challenge test?
Because there are no broadly validated reference ranges for provoked urine and the test, in studies, could not reliably separate symptom pictures from mere exposures. Without a clean comparison value, a high result is easily misinterpreted. This criticism is justified and belongs to an honest assessment.
What happens after an abnormal test?
An abnormal value is not a treatment order but a reason to review the overall picture: history of sources, symptoms, mineral status and course over time. Only from this combined view does it emerge whether a structured chelation could be sensible or whether other causes are in the foreground.
Which metal does the DMPS test show best?
DMPS binds above all sulphur-affine metals and increases mercury excretion in particular markedly, in studies by three to over a hundredfold. Arsenic and, to a lesser extent, lead are also captured. For chronic cadmium burden, by contrast, DMPS is not a suitable tool.
Read on in the heavy metals cluster
This article is one building block. If you want to go deeper, these paths lead onward, from the big overview through the measurement methods to chelation.
Pillar: Heavy metals
The big overview of sources, metals and the logic of chelation
Main articleBlood, urine or hair
Which measurement method really works for which question
Hair mineral analysis
Possibilities and limits of hair analysis for metals
Chelation therapy
From test to chelation: procedure, duration and what to expect
Anyone considering the test because of typical triggering complaints will also find points of connection in the articles on brain fog from heavy metals and on persistent fatigue. For the individual chelating agents there are separate articles, for example on DMSA and on the side effects and risks of chelation therapy.
Sources
Transparency note: The human evidence for metal mobilisation by DMPS is solid, but is based predominantly on small observational and challenge studies, not on large randomised trials. For the diagnostic question of whether the test proves a poisoning, the evidence is negative: validated reference values are lacking, the predictive value is low, and several medical societies advise against the test as a sole diagnostic instrument. The article therefore consistently presents the test as a measurement of mobilisability in context.
- Torres-Alanis O, Garza-Ocanas L, Bernal MA, Pineyro-Lopez A. Urinary excretion of trace elements in humans after sodium 2,3-dimercaptopropane-1-sulfonate challenge test. J Toxicol Clin Toxicol. 2000;38(7):697-700. DOI: 10.1081/clt-100102382 [Case series, human study, n=11]
- Ruha AM. Recommendations for provoked challenge urine testing. J Med Toxicol. 2013;9(4):318-325. DOI: 10.1007/s13181-013-0350-7 [Review, critical, practice recommendation]
- Weiss ST, Campleman S, Wax P, McGill W, Brent J. Failure of chelator-provoked urine testing results to predict heavy metal toxicity in a prospective cohort. Clin Toxicol (Phila). 2021;60(2):191-196. DOI: 10.1080/15563650.2021.1941626 [Cohort, prospective, n=74]
- Aposhian HV. Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS). Environ Health Perspect. 1998;106 Suppl 4:1017-1025. DOI: 10.1289/ehp.98106s41017 [Review, human study, protocol]
- Vamnes JS, Eide R, Isrenn R, Hol PJ, Gjerdet NR. Diagnostic value of a chelating agent in patients with symptoms allegedly caused by amalgam fillings. J Dent Res. 2000;79(3):868-874. DOI: 10.1177/00220345000790031401 [Cohort, controlled clinical, n=80]
- Hurlbut KM, Maiorino RM, Mayersohn M, Dart RC, Bruce DC, Aposhian HV. Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther. 1994;268(2):662-668. PMID: 8113976 [Case series, pharmacokinetic human study, n=5]
- Molin M, Schutz A, Skerfving S, Sallsten G. Mobilized mercury in subjects with varying exposure to elemental mercury vapour. Int Arch Occup Environ Health. 1991;63(3):187-192. DOI: 10.1007/BF00381567 [Cohort, human study, n=41]
- Gonzalez-Ramirez D, Maiorino RM, Zuniga-Charles M, et al. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. II. Urinary mercury, porphyrins and neurobehavioral changes of dental workers. J Pharmacol Exp Ther. 1995;272(1):264-274. PMID: 7815341 [Cohort, occupational exposure, human study, n=28]
- Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, et al. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride. J Pharmacol Exp Ther. 1996;277(2):938-944. PMID: 8627576 [Cohort, occupational exposure, human study, n=28]
- Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995;97(1-3):23-38. DOI: 10.1016/0300-483x(95)02965-b [Mechanism review]
- Zander D, Ewers U, Freier I, Brockhaus A. Quecksilbermobilisation durch DMPS (Dimaval) bei Personen mit und ohne Amalgamfüllungen. Zentralbl Hyg Umweltmed. 1992;192(5):447-454. PMID: 1554403 [Cohort, human study, n=29]
- Nerudova J, Cabelkova Z, Frantik E, et al. Mobilization of mercury by DMPS in occupationally exposed workers and in model experiments on rats. Int J Occup Med Environ Health. 2000;13(2):131-146. PMID: 10967843 [Cohort, human study n=75; in vivo rat]
- Aposhian HV, Bruce DC, Alter W, Dart RC, Hurlbut KM, Aposhian MM. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with dental amalgam score. FASEB J. 1992;6(7):2472-2476. DOI: 10.1096/fasebj.6.7.1563599 [Cohort, human study, amalgam score]
- Abouyannis M, Nyambura YK, Ngome S, et al. Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 dose-escalation safety trial. EBioMedicine. 2025;113:105600. DOI: 10.1016/j.ebiom.2025.105600 [Real-world phase 1 safety study, n=64]
- Vamnes JS, Eide R, Isrenn R, Hol PJ, Gjerdet NR. Blood mercury following DMPS administration to subjects with and without dental amalgam. Sci Total Environ. 2003;308(1-3):63-71. DOI: 10.1016/S0048-9697(02)00630-7 [Cohort, controlled clinical, n=80]